Home > Boards > US Listed > Biotechs > Synthetic Biologics, Inc. (SYN)

Low float. Not sure if anyone around

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
BooDog Member Profile
 
Followed By 179
Posts 19,171
Boards Moderated 4
Alias Born 08/03/06
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2019 4:38:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:21:33 PM
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results PR Newswire (US) - 11/4/2019 4:10:00 PM
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 PR Newswire (US) - 10/28/2019 4:30:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 9/26/2019 5:05:45 PM
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome... PR Newswire (US) - 9/26/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/6/2019 6:03:48 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2019 5:01:01 PM
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 PR Newswire (US) - 8/1/2019 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 7/15/2019 5:16:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2019 7:06:03 AM
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire (US) - 7/1/2019 7:00:00 AM
Sýn hf. : First quarter results in a profit of ISK 670 million GlobeNewswire - 5/15/2019 12:26:39 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 5:06:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:17:37 PM
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results PR Newswire (US) - 5/8/2019 4:10:00 PM
Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019 PR Newswire (US) - 4/30/2019 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2019 5:15:49 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/3/2019 5:15:25 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/1/2019 5:02:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/4/2019 5:03:56 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/27/2019 5:05:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2019 4:19:26 PM
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results PR Newswire (US) - 2/27/2019 4:10:00 PM
Sýn hf. : Q4 Investors presentation GlobeNewswire - 2/27/2019 3:03:57 PM
BooDog   Thursday, 02/28/19 06:49:00 AM
Re: None
Post # of 8128 
Low float. Not sure if anyone around here listened in on the conference call yesterday.



Clinical Development and Operational Update

•Commenced enrollment of Phase 2b investigator-sponsored clinical study of SYN-010, for the treatment of IBS-C,

•Held an End-of-Phase 2 meeting with FDA and confirmed key elements of the Phase 3 clinical program to support a marketing application for SYN-004 (ribaxamase),

•Continued to evaluate a potential secondary indication for SYN-004 (ribaxamase) for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplantation (HCT) recipients,

•Identified potential clinical indications for SYN-020 (intestinal alkaline phosphatase) in areas of unmet medical need including, enterocolitis associated with radiation therapy for cancer and autoimmune enterocolitis associated with checkpoint inhibitor therapy for cancer,

•Strengthened balance sheet by raising gross proceeds of approximately $18.6 million from the closing of a public offering of common stock and Series B Convertible Preferred Stock in support of our lead clinical development activities



https://www.webcaster4.com/Webcast/Page/1096/29346



"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist